Extended use of intravenous bisphosphonate therapy for the prevention of skeletal complications in patients with cancer

Cancer Investigation

Volumn 27, Issue 10, 2009, Pages 984-988

  Crawford, Brooke S ^a   McNulty, Robert M ^a   Kraut, Eric H ^a   Turowski, Robert C ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

Bisphosphonate; Breast cancers; Late effects of therapy; Lung cancer; Myeloma; Osteonecrosis of the jaws; Pamidronate; Supportive care and symptom control; Zoledronic acid

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

ADULT; AGED; ARTICLE; BONE DISEASE; BREAST CANCER; FEMALE; HUMAN; INCIDENCE; JAW OSTEONECROSIS; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NEOPLASM; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; FEMALE; FRACTURES, BONE; HUMANS; IMIDAZOLES; JAW DISEASES; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; OSTEONECROSIS; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SPINAL CORD COMPRESSION; TIME FACTORS; TREATMENT OUTCOME;

EID: 70450211381     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357900902783203     Document Type: Article

References (22)

1. Coleman, R. Bisphosphonates: Clinical experience. Oncologist 2004, 9, 14-27.
2. Rosen, L.; Gordon, D.; Kaminski, M.; et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advance multiple myeloma or breast carcinoma: A randomized, doubleblind, multicenter, comparative trial. Cancer 2003, 98, 1735-1744.
3. Saad, F.; Gleason, D.; Murray, R.; et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004, 6, 879-882. (Pubitemid 38807610)
4. Rosen, L.; Gordon, D.; Tchekmedyian, S.; et al. Zoledronic acid vs. placebo in the treatment of skeletal metastasis in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial-the zoledronic acid lung cancer and other solid tumors study group. J Clin Oncol 2003, 21, 3150-3157.
5. Berenson, J.R.; Hillner, B.E.; Kyle, R.A.; et al. American society of clinical oncology clinical practice guidelines: The role of bisphosphonates in multiple myeloma. J Clin Oncol 2002, 20, 3719-3736.
6. Hillner, B.E.; Ingle, J.N.; Chlebowski, R.T.; et al. American society of clinical oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003, 21, 4042-4057.
7. Kyle, R.A.; Yee, G.C.; Somerfield, M.R.; et al. American society of clinical oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 2007, 25, 1-9.
8. Ali, S.; Hortobagyi, E.; Harvey, H.; et al. Safety and efficacy of bisphosphonates beyond 24 months in cancer patients. J Clin Oncol 2001, 19, 3434-3437.
9. Mehrotra, B.; Fantasia, J.; Nissel-Horowitz, S.; Vinarsky, S.; Ruggiero, S. Osteonecrosis of the maxilla: An unusual complication of prolonged bisphosphonate therapy. A case report. Proc Am Soc Clin Oncol 2003, 22, 795.
10. Rosenberg, T.; Ruggiero, S. Osteonecrosis of the jaws associated with the use of bisphosphonates. J oral Maxillofac Surg 2003, 61(Suppl. 1), 60.
11. Marx, R. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg 2003, 61, 1115-1117.
12. Migliorati, C. Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol 2003, 21, 4253-4254.
13. www.fda.gov/medwatch/SAFETY/2004/ZometaHCP.pdf.
14. Aredia® Package Insert. East Hanover, New Jersey: Novartis, 2003.
15. Zometa® Package Insert. East Hanover, New Jersey: Novartis, 2003.
16. Personal correspondence. East Hanover, New Jersey: Novartis; October 09, 2007 vs. Personal Communication to Robert Turowski from Linda Weiss, Pharm.D., Senior Medical Information Specialist, Medical Information, Communication & Education. Novartis Pharmaceuticals Corporation. October 9, 2007 (Letter).
17. Durie, B.; Katz, M.; Crowley, J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005, 353, 99-102.
18. Woo, S.; Hellstein, J.; Kalmar, J. Systemic review: Bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006, 144, 753-761.
19. Mavrokokko, T.; Cheng, A.; Stein, B.; et al. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007, 65, 415-423.
20. Badros, A.; Weikel, D.; Salama, A.; Goloubeva, O.; et al. Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors. J Clin Oncol 2006, 24, 945-952.
21. Ruggiero, S.; Gralow, J.; Marx, R.; Hoff, A. Practical guidelines for the prevention, diagnosis and treatment of osteonecrosis of the jaw in patients with cancer. J Clin Oncol Pract 2006, 2, 7-14.
22. Takeyama, S.; Shinoda, H. Pharmacologic actions and pharmacokinetics of bisphosphonates. Clin Calcium 2003, 13, 115-121.